Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (413)	2/16/2005 9:52:04 AM
From: D.Lu	Read Replies (2) \| Respond to of 946

Do you think the market has discounted these results?

To: Icebrg who wrote (413)	2/16/2005 9:07:30 PM
From: gcrispin	Respond to of 946

In a Mescape article summarizing the highlights of the Chemotherapy Foundation Symposium XXI, the following was noted by Dr. Burris: Looking at a summary of toxicities from a CT-2103 database, Dr. Burris noted that although the incidence of neutropenia appeared lower than that seen with similar doses of paclitaxel, this adverse effect is still clearly the dose-limiting factor for CT-2103 at doses greater than 235 mg/m2. Nine percent of patients on 175 mg/m2, 11% on 210 mg/m2, and 27% of patients on 235 mg/m2 have had grade 4 neutropenia. Cumulative neurotoxicity has also been observed, especially in patients who have received prior neurotoxic agents.